513 results on '"Qi, Xiaowei"'
Search Results
2. Low NDRG2, regulated by the MYC/MIZ-1 complex and methylation, predicts poor outcomes in DLBCL patients
3. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
4. Development of a chemiluminescence assay for tissue plasminogen activator inhibitor complex and its applicability to gastric cancer
5. Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis
6. Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients
7. Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)
8. First identification of microplastics in human uterine fibroids and myometrium
9. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial
10. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
11. Docetaxel-loaded pH/ROS dual-responsive nanoparticles with self-supplied ROS for inhibiting metastasis and enhancing immunotherapy of breast cancer
12. Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data
13. Crystal size, a key character of lactose crystallization affecting microstructure, surface chemistry and reconstitution of milk powder
14. Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study)
15. PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
16. Lysine demethylase 5A promotes prostate adenocarcinoma progression by suppressing microRNA-330-3p expression and activating the COPB2/PI3K/AKT axis in an ETS1-dependent manner
17. An overview of the research progress of BRCA gene mutations in breast cancer
18. Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis
19. The relationship between PIK3CA mutations and survival in patients with human epidermal growth factor receptor 2–positive breast cancer receiving pyrotinib combined with trastuzumab for neoadjuvant treatment.
20. Robotic versus open surgery for thyroidectomy and modified radical neck dissection in patients with papillary thyroid carcinoma with clinical lateral neck node metastasis (cN1b): Effectiveness and safety, oncological outcomes and long-term quality of life.
21. Mechanism study on fig exosome-like nanoparticles inhibiting the progression of bone metastasis in breast cancer.
22. Effect of transcription factor WT1 on triple-negative breast cancer metastasis through PFKFB4-mediated glycolysis.
23. A comparative study of SiC MOSFETs with and without integrated SBD
24. Gallium complex K6 inhibits colorectal cancer by increasing ROS levels to induce DNA damage and enhance phosphatase and tensin homolog activity.
25. Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer
26. Multifaceted roles and functions of SOX30 in human cancer
27. Metabolomics analysis reveals characteristic metabolites in different levels of oxaliplatin‐induced neurotoxicity.
28. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
29. 5-Fluorouracil resistant CRC cells derived exosomes promote cancer-associated fibroblasts secreting more CXCL12
30. Construction of a ferroptosis-based prognostic model for breast cancer helps to discriminate high/low risk groups and treatment priority
31. A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer
32. Integrated endotoxin-adsorption and antibacterial properties of platelet-membrane-coated copper silicate hollow microspheres for wound healing
33. Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation
34. First report of in-situ preservation of a subcapsular parathyroid gland through super-meticulous capsular dissection during robotic radical thyroidectomy
35. Development of a Chemiluminescence Assay for Tissue Plasminogen Activator Inhibitor Complex and Its Applicability to Gastric Cancer
36. Prognostic Value of Combined LMR and CEA Dynamic Monitoring in Postoperative Colorectal Cancer Patients
37. B-Type Natriuretic Peptide Can Distinguish Ischemic Stroke Subtypes Better than Other Cardiac Biomarkers
38. Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin α5β1 interaction and Akt signaling pathway
39. Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
40. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
41. Investigating the role of FADS family members in breast cancer based on bioinformatic analysis and experimental validation
42. Figure S4 from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
43. Supplementary Materials and Methods from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
44. Conventional vs Minimally Invasive Breast Surgery—Reply
45. Frequent EGFR exon 20 insertion in the so‐called peripheral‐type squamous cell neoplasm of uncertain malignant potential: a variant of bronchiolar adenoma or under‐recognised entity?
46. Abstract OT2-22-01: Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
47. Abstract P1-11-18: The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China
48. Abstract P5-02-52: Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis
49. Abstract P5-10-01: Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial
50. Abstract P6-10-02: Self-assembled nano drugs of pyrotinib and indocyanine green based on photothermal photodynamic therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.